New Results

CD47 as a potential biomarker for the early diagnosis of severe COVID-19

Katie-May McLaughlin, Denisa Bojkova, Marco Bechtel, Joshua D. Kandler, Philipp Reus, Trang Le, Julian U. G. Wagner, Sandra Ciesek, Mark N. Wass, Martin Michaelis, Jindrich Cinatl jr.
doi: https://doi.org/10.1101/2021.03.01.433404

Abstract

The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. Antiviral interventions are only effective prior to the onset of hyperinflammation. Hence, biomarkers are needed for the early identification and treatment of high-risk patients. Here, we show in a range of model systems and data from post mortem samples that SARS-CoV-2 infection results in increased levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells. Systematic literature searches also indicated that known risk factors such as older age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular disease, vasoconstriction, and hypertension, conditions which may predispose SARS-CoV-2-infected individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury. Hence, CD47 is a candidate biomarker for severe COVID-19. Further research will have to show whether CD47 is a reliable diagnostic marker for the early identification of COVID-19 patients requiring antiviral therapy.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing coronavirus disease 2019 (COVID-19) outbreak [Hokello et al., 2020; Chilamakuri & Agarwal, 2021], which has resulted in more than 100 million confirmed cases and more that 2 million confirmed COVID-19-associated deaths so far [Dong et al., 2020].

The first COVID-19 vaccines have been developed [Chilamakuri & Agarwal, 2021], and their roll-out has started in many countries. However, it will take a significant time until large parts of the world population will be vaccinated, and there is growing concern about the emergence of escape variants that can bypass immunity conferred by the current vaccines and previous SARS-CoV-2 infections [Andreano et al., 2020; Kemp et al., 2020; Liu et al., 2020; Weisblum et al., 2020; Sabino et al, 2021; Wibmer et al., 2021]. For the foreseeable future, there will thus be a need for improved COVID-19 therapies.

Currently, the therapeutic options for COVID-19 are still very limited [Chilamakuri & Agarwal, 2021; Rebold et al., 2021]. COVID-19 therapies can either directly inhibit SARS-CoV-2 replication or target other COVID-19-associated pathophysiological processes, such as corticosteroids that are anticipated to control COVID-19-related cytokine storm and hyperinflammation [Pum et al., 2021]. Dexamethasone and potentially other corticosteroids increase survival in patients who depend on oxygen support [RECOVERY Collaborative Group, 2020; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, 2020]. In a controlled open-label trial, dexamethasone reduced mortality in patients receiving oxygen with (from 41.1% to 29.3%) or without (from 26.2% to 23.3%) mechanical ventilation, but increased mortality in patients not requiring oxygen support [RECOVERY Collaborative Group, 2020]. Other immunomodulatory therapy candidates are being tested, but conclusive results are pending [Rebold et al., 2021]. Further COVID-19 therapeutics under investigations include anticoagulants that target COVID-19-induced systemic coagulation and thrombosis (coagulopathy) [Hadid et al., 2020].

However, it would be much better to have effective antiviral treatments that reliably prevent COVID-19 disease progression to a stage when immunomodulators and anticoagulants are needed. The antiviral drug remdesivir was initially described to reduce recovery time from 15 to ten days and 29-day mortality from 15.2% to 11.4% [Beigel et al., 2020; Rebold et al., 2021]. However, other trials did not confirm this and conclusive evidence on the efficacy of remdesivir remains to be established [Rebold et al., 2021]. The JAK inhibitor baricitinib, which interferes with cytokine signalling, was reported to improve therapy outcomes in combination with remdesivir in a double-blind, randomised, placebo-controlled trial, in which patients were either treated with remdesivir plus baricitinib or remdesivir plus placebo [Kalil et al., 2020]. Moreover, convalescent sera and monoclonal antibodies are under clinical investigation for COVID-19 treatment [Tuccori et al., 2020; Devarasetti et al., 2021].

Ideally, antiviral therapies are used early in the disease course to prevent disease progression to the later immunopathology-driven stages [Weinreich et al., 2021]. However, only a small proportion of patients develops severe disease [Salzberger et al., 2020]. Therefore, biomarkers are required that identify patients, who will develop severe disease, as early as possible.

Here, we investigated the potential of the ubiquitously expressed cell surface glycoprotein CD47 as biomarker for the identification of high-risk COVID-19 patients. CD47 is the receptor of thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPα). CD47 interaction with SIRPα inhibits the activation of macrophages and dendritic cells and thrombospondin-1/ CD47 signalling inhibits T cell activation [Cham et al., 2020; Kaur et al., 2020]. High CD47 expression prevents immune recognition of cancer and virus-infected cells [Cham et al., 2020; Kaur et al., 2020].

2. Materials and Methods

2.1 Cell culture

Calu-3 cells (ATCC) were grown at 37°C in minimal essential medium (MEM) supplemented with 10% foetal bovine serum (FBS), 100 IU/mL penicillin, and 100 μg/mL of streptomycin. All culture reagents were purchased from Sigma. Cells were regularly authenticated by short tandem repeat (STR) analysis and tested for mycoplasma contamination.

Primary human bronchial epithelial cells were purchased from ScienceCell. For differentiation to air-liquid interface (ALI) cultures, the cells were thawed and passaged once in PneumaCult-Ex Medium (StemCell technologies) and then seeded on transwell inserts (12 well plate, Sarstedt) at 4×104 cells/insert. Once cell layers reached confluency, medium on the apical side of the transwell was removed, and medium in the basal chamber was replaced with PneumaCult ALI Maintenance Medium (StemCell Technologies) including Antibiotic/Antimycotic solution (Sigma Aldrich) and MycoZap Plus PR (Lonza). During a period of four weeks, medium was changed and cell layers were washed with PBS every other day. Criteria for successful differentiation were the development of ciliated cells and ciliary movement, an increase in transepithelial electric resistance indicative of the formation of tight junctions, and mucus production.

2.2 Virus infection

SARS-CoV-2/7/Human/2020/Frankfurt (SARS-CoV-2/FFM7) was isolated and cultivated in Caco2 cells (DSMZ) as previously described [Hoehl et al., 2020; Toptan et al., 2020]. Virus titres were determined as TCID50/ml in confluent cells in 96-well microtiter plates [Cinatl et al., 2003; Cinatl et al., 2005].

2.3 Antiviral assay

Confluent layers of CaCo-2 cells in 96-well plates were infected with SARS-CoV–2 FFM7 at a MOI of 0.01. Virus was added simultaneously with tested compound. 24 h post infection, cells were fixed with acetone:methanol (40:60) solution and immunostaining of spike protein was performed to determine infection rate. Briefly, a monoclonal antibody directed against the spike protein of SARS-CoV-2 (1:1,500, Sino Biological) was detected with a peroxidase-conjugated anti-rabbit secondary antibody (1:1,000, Dianova), followed by addition of AEC substrate. The spike positive area was scanned and quantified by automated plate reader. The results are expressed as percentage of infection relative to virus control which received no drug.

2.4 Western blot

Cells were lysed using Triton-X-100 sample buffer, and proteins were separated by SDS-PAGE. Detection occurred by using specific antibodies against CD47 (1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinity™, # 130-101-343, Miltenyi Biotec), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological), and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen). Protein bands were visualized and quantified by laser-induced fluorescence using infrared scanner for protein quantification (Odyssey, Li-Cor Biosciences).

2.5. qPCR

SARS-CoV-2 RNA from cell culture supernatant samples was isolated using AVL buffer and the QIAamp Viral RNA Kit (Qiagen) according to the manufacturer’s instructions. Absorbance-based quantification of the RNA yield was performed using the Genesys 10S UV-Vis Spectrophotometer (Thermo Scientific). RNA was subjected to OneStep qRT-PCR analysis using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs) and a CFX96 Real-Time System, C1000 Touch Thermal Cycler. Primers were adapted from the WHO protocol29 targeting the open reading frame for RNA-dependent RNA polymerase (RdRp): RdRP_SARSr-F2 (GTG ARA TGG TCA TGT GTG GCG G) and RdRP_SARSr-R1 (CAR ATG TTA AAS ACA CTA TTA GCA TA) using 0.4 µM per reaction. Standard curves were created using plasmid DNA (pEX-A128-RdRP) harbouring the corresponding amplicon regions for RdRP target sequence according to GenBank Accession number NC_045512. For each condition three biological replicates were used. Mean and standard deviation were calculated for each group.

2.6 Data acquisition and analysis

Normalized protein abundance data from SARS-CoV-2-infected Caco-2 cells were derived from a recent publication [Bojkova et al., 2020]. Data were subsequently normalised using summed intensity normalization for sample loading, followed by internal reference scaling and Trimmed mean of M normalization. Mean protein abundance was plotted using the function ggdotplot of the R package ggpubr. P-values were determined by two-sided student’s t-test

Raw read counts from post-mortem samples of two COVID-19 patients and two healthy controls, as well as mock infected and SARS-CoV-2-infected Calu-3 cells, were derived from a recent publication [Blanco-Melo et al., 2020] via the gene expression omnibus (GEO) database (accession: GSE147507) and processed using DESeq2. Normalised gene counts were plotted using the function ggdotplot of the R package ggpubr. P-values were determined by two-sided student’s t-test

2.6 Literature review

Relevant articles were identified by using the search terms ‘CD47 aging’, ‘CD47 hypertension’, ‘CD47 diabetes’, and ‘CD47 obesity’ in PubMed (https://pubmed.ncbi.nlm.nih.gov). Original articles in English were included into the analysis, when they contained on the influence of aging, diabetes, diabetes, or obesity on CD47 expression levels and/ or the relevance of CD47 with regard to pathological conditions observed in severe COVID-19.

3. Results

3.1 SARS-CoV-2 infection results in enhanced CD47 expression

A publicly available proteomics dataset [Bojkova et al., 2020] indicated increased in CD47 expression in SARS-CoV-2-infected Caco2 colorectal carcinoma cells (Figure 1A). We also detected enhanced CD47 levels in SARS-CoV-2-infected primary human bronchial epithelial cells (HBEpiC) grown in air liquid interface (ALI) cultures [Bojkova et al., 2020A] and Calu-3 lung cancer cells (Figure 1B). Analysis of transcriptomics data from another study also indicated increased CD47 levels in SARS-CoV-2 -infected Calu-3 cells (Suppl. Figure 2) and in post mortem lung samples from COVID-19 patients (Figure 1C) [Blanco-Melo et al., 2020].

Figure 1.
Figure 1.

SARS-CoV-2 infection is associated with increased CD47 levels. A) TF protein abundance in uninfected (control) and SARS-CoV-2-infected (virus) Caco-2 cells (data derived from [Bojkova et al., 2020]. P-values were determined by two-sided Student’s t-test. B) CD47 and SARS-CoV-2 N protein levels and virus titres (genomic RNA determined by PCR) in SARS-CoV-2 strain FFM7 (MOI 1)-infected air-liquid interface cultures of primary human bronchial epithelial (HBE) cells and SARS-CoV-2 strain FFM7 (MOI 0.1)-infected Calu-3 cells. Uncropped blots are provided in Suppl. Figure 1. C) CD47 mRNA levels in post mortem samples from COVID-19 patients (data derived from [Blanco-Melo et al., 2020]). P-values were determined by two-sided Student’s t-test.

3.2 CD47 and COVID-19 risk factors

To further investigate a potential role of CD47 as biomarker indicating a high risk from COVID-19, we performed systematic literature searches on the relationship of CD47 and the known COVID-19 risk factors ‘ageing’, ‘diabetes’, and ‘obesity’.

3.2.1 CD47 and ageing

The risk of severe COVID-19 disease and COVID-19 death increases with age [Hokello et al., 2020]. A literature search in PubMed (https://pubmed.ncbi.nlm.nih.gov, 17th February 2020) using the terms ‘CD47’ and aging’ resulted in 62 hits (Suppl. Table 1). Eight of these articles contained information that support a link between age-related increased CD47 levels and an elevated risk of severe COVID-19 (Figure 2, Suppl. Table 1). One article suggested that alpha-tocopherol reduced age-associated streptococcus pneumoniae lung infection in mice by CD47 downregulation [Ghanem et al., 2015], which is in accordance with the known immunosuppressive functions of CD47 [Cham et al., 2020; Kaur et al., 2020].

Figure 2.
Figure 2.

Results of the PubMed (https://pubmed.ncbi.nlm.nih.gov) literature search for “CD47 aging” (A) and “CD47 hypertension” (B). C) Overview figure of the data derived from the literature searches. Age-related increased CD47 levels may contribute to pathogenic conditions associated with severe COVID-19.

The remaining seven articles reported on age-related increased CD47 levels in vascular cells that are associated with reduced vasodilatation and blood flow (Suppl. Table 1), as CD47 signalling inhibits NO-mediated activation of soluble guanylate cyclase and in turn vasodilatation [Isenberg et al., 2008; Miller et al., 2010]. Since reduced vasodilatation can cause hypertension [Touyz et al., 2018], we performed a follow-up literature search using the search terms “CD47 hypertension” (Suppl. Table 2). This resulted in 20 hits, including a further seven relevant studies (Figure 2B, Suppl. Table 2).

Initial experiments showed that loss or inhibition of CD47 prevented age- and diet-induced vasculopathy and reduced damage caused by ischaemic injury in mice [Isenberg et al., 2007]. CD47-deficient mice indicated that CD47 functions as vasopressor and were also shown to be leaner and to display enhanced physical performance and a more efficient metabolism [Isenberg et al., 2009; Frazier et al., 2011]. In agreement, CD47 was upregulated in clinical pulmonary hypertension and contributed to pulmonary arterial vasculopathy and dysfunction in mouse models [Bauer et al., 2012; Rogers et al., 2017]. Age-related increased CD47 levels further affected peripheral blood flow and wound healing in mice [Rogers et al., 2013] and NO-mediated vasodilatation of coronary arterioles of rats [Nevitt et al., 2016]. Moreover, thrombospondin-1/ CD47 signalling was shown to induce ageing-associated senescence in endothelial cells [Gao et al., 2016; Meijles et al., 2017] and age-associated deterioration in angiogenesis, blood flow, and glucose homeostasis [Ghimire et al., 2020].

Increased CD47 levels were also detected in the lung of a sickle cell disease patient with pulmonary arterial hypertension, and vasculopathy and pulmonary hypertension were reduced in a CD47-null mouse model of sickle cell disease [Rogers et al., 2013a; Novelli et al., 2019]. Finally, anti-CD47 antibodies reversed fibrosis in various organs in mouse models [Wernig et al., 2017], which may be relevant in the context of COVID-19-associated pulmonary fibrosis [Leeming et al., 2021].

In addition to immunosuppressive activity, ageing-related increased CD47 levels may thus be involved in vascular disease, vasoconstriction, and hypertension and predispose COVID-19 patients to related pathologies such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury [Soto-Pantoja et al., 2013; Rogers et al., 2017a; Cruz Rodriguez et al., 2020; Fabrizi et al., 2020; Karmouty-Quintana et al., 2020; Scutelnic and Heldner, 2020; Leeming et al., 2021; Sanghvi et al., 2021; Shah et al., 2021].

3.2.2 CD47 and diabetes

Diabetes has been associated with an increased risk of severe COVID-19 and COVID-19-related death [Shah et al., 2021]. A PubMed search for “CD47 diabetes” produced 47 hits, nine of which reported on increased CD47 levels in response to hyperglycaemia and/ or diabetes (Figure 3, Suppl. Table 3).

Figure 3.
Figure 3.

Results of the PubMed (https://pubmed.ncbi.nlm.nih.gov) literature search for “CD47 diabetes” (A). B) Overview figure of the data derived from the literature search. Hyperglycaemia- and diabetes-induced increased CD47 levels may contribute to immune escape of SARS-CoV-2-infected cells.

Hyperglycaemia protected CD47 from cleavage resulting in increased CD47 levels [Maile et al., 2008; 2009; 2010; 2012]. In agreement, increased CD47 levels were detected in various cell types and tissues in rat diabetes models and diabetes patients [Abdul-Rahman et al., 2012; Abu El-Asrar et al., 2013; Wang et al., 2014; Bitar, 2019]. Therefore, diabetes-induced increased CD47 levels may interfere with the recognition of SARS-CoV-2-infected cells by the immune system [Cham et al., 2020; Kaur et al., 2020].

3.2.3 CD47 and obesity

As obesity is another risk factor for severe COVID-19 [Shah et al., 2021], we also performed a PubMed search for “CD47 obesity”, which resulted in eight hits, two of which provided potentially relevant information (Suppl. Table 4). Results indicated that CD47-deficient mice were leaner, probably as a consequence of elevated lipolysis [Maimaitiyiming et al., 2015; Norman-Burgdolf et al., 2020]. Hence, low CD47 levels may be associated both with lower weight and increased immune recognition of virus-infected cells [Maimaitiyiming et al., 2015; Cham et al., 2020; Kaur et al., 2020; Norman-Burgdolf et al., 2020], but there is no direct evidence suggesting that obesity may also directly increase CD47 expression. However, obesity may at least indirectly contribute to enhanced CD47 levels as risk factor for diabetes [Shah et al., 2021].

4. Discussion

Here, we show that SARS-CoV-2 infection is associated with increased CD47 expression in a range of model systems and in post mortem samples from COVID-19 patients. CD47 exerts immunosuppressive activity via interaction with SIRPα on immune cells and as thrombospondin-1 receptor [Cham et al., 2020; Kaur et al., 2020]. In this context, human CD47 expression is discussed as a strategy to enable the xenotransplantation of organs from pigs to humans [Cooper et al., 2019; Hosny et al., 2021]. Moreover, high CD47 expression is an immune escape mechanism observed on cancer cells, and anti-CD47 antibodies are under investigation as cancer immunotherapeutics [Feng et al., 2020; Kaur et al., 2020]. Due its immunosuppressive action, CD47 expression is also discussed as a target for the treatment of viral and bacterial pathogens including SARS-CoV-2 [Cham et al., 2020; Oronsky et al., 2020a; Tal et al., 2020]. Thus, our data indicating increased CD47 levels in a range of SARS-CoV-2 infection models and clinical samples further support the potential role of CD47 as drug target for the mediation of a more effective antiviral immune response.

Older age, diabetes, and obesity are known risk factors for COVID-19 morbidity and mortality [Hokello et al., 2020; Shah et al., 2021]. Hence, we performed a series of systematic reviews to identify potential connections between CD47 and these processes. Results indicated an ageing-related increase in CD47 expression, which may contribute the increased COVID-19 vulnerability in older patients [Hokello et al., 2020]. Moreover, high CD47 levels are known to be involved in vascular disease, vasoconstriction, and hypertension, which may predispose SARS-CoV-2-infected individuals to various conditions associated with severe COVID-19 related, including pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury [Soto-Pantoja et al., 2013; Rogers et al., 2017a; Cruz Rodriguez et al., 2020; Fabrizi et al., 2020; Karmouty-Quintana et al., 2020; Scutelnic and Heldner, 2020; Leeming et al., 2021; Sanghvi et al., 2021; Shah et al., 2021].

High CD47 levels have also been reported as a consequence of hyperglycaemia and diabetes, which may contribute to the high risk of severe COVID-19 in diabetic patients [Shah et al., 2021]. Although there is no known direct impact of obesity on CD47 levels, obesity is associated with an increased risk of diabetes and other ageing-related conditions such as hypertension that may result in elevated COVID-19 vulnerability [Shah et al., 2021].

5. Conclusions

Severe COVID-19 disease is the consequence of hyperinflammation (‘cytokine storm’) in response to SARS-CoV-2 infection [Jacques and Apedaile, 2020; Nowill and Campos-Lima, 2020; Gustine and Jones, 2021]. Hence, the optimal time window for antiviral intervention is as early as possible to prevent disease progression to severe stages driven by immunopathology [Weinreich et al., 2021]. Since the vast majority of cases are mild or even asymptomatic [Salzberger et al., 2020], biomarkers are required to identify and treat individuals early, who are at high risk of severe COVID-19.

Here, we have identified CD47 as a candidate biomarker for severe COVID-19. SARS-CoV-2 infection results in enhanced CD47 expression, which is known to interfere with the host immune response. Moreover, CD47 levels are elevated in groups at high risk from COVID-19 such as older individuals and individuals with hypertension and/ or diabetes. Thus, high CD47 levels may predispose these groups to severe COVID-19. Further research will have to show whether CD47 is a reliable diagnostic marker for the early identification of COVID-19 patients requiring antiviral therapy.

Conflict of interest

Nothing to declare.

References

  1. ↵
    Abdul-Rahman O, Sasvari-Szekely M, Ver A, Rosta K, Szasz BK, Kereszturi E, Keszler G. Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics. 2012 Feb 27;13:81. doi: 10.1186/1471-2164-13-81.
    OpenUrlCrossRefPubMed
  2. ↵
    Abu El-Asrar AM, Nawaz MI, Ola MS, De Hertogh G, Opdenakker G, Geboes K. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy. Acta Ophthalmol. 2013 May;91(3):e169–77. doi: 10.1111/aos.12035.
    OpenUrlCrossRefPubMed
  3. Allen LB, Capps BE, Miller EC, Clemmons DR, Maile LA. Glucose-oxidized low-density lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage. Endocrinology. 2009 Mar;150(3):1321–9. doi: 10.1210/en.2008-1090.
    OpenUrlCrossRefPubMed
  4. ↵
    Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Monego SD, Pantano E, Manganaro N, Manenti A, Manna R, Casa E, Hyseni I, Benincasa L, Montomoli E, Amaro RE, McLellan JS, Rappuoli R. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 Dec 28:2020.12.28.424451. doi: 10.1101/2020.12.28.424451.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo-Cuaresma M, Pilewski JM, Champion HC, Zuckerbraun BS, Calzada MJ, Isenberg JS. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res. 2012 Mar 15;93(4):682–93. doi: 10.1093/cvr/cvr356.
    OpenUrlCrossRefPubMed
  6. ↵
    Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813–1826. doi: 10.1056/NEJMoa2007764.
    OpenUrlCrossRefPubMed
  7. ↵
    Bitar MS. Diabetes Impairs Angiogenesis and Induces Endothelial Cell Senescence by Up-Regulating Thrombospondin-CD47-Dependent Signaling. Int J Mol Sci. 2019 Feb 4;20(3):673. doi: 10.3390/ijms20030673.
    OpenUrlCrossRef
  8. ↵
    Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026.
    OpenUrlCrossRefPubMed
  9. ↵
    Bojkova, D.; Klann, K.; Koch, B.; Widera, M.; Krause, D.; Ciesek, S.; Cinatl, J.; Münch, C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 2020 May 14. doi: 10.1038/s41586-020-2332-7.
    OpenUrlCrossRefPubMed
  10. ↵
    Bojkova D, Bechtel M, McLaughlin KM, McGreig JE, Klann K, Bellinghausen C, Rohde G, Jonigk D, Braubach P, Ciesek S, Münch C, Wass MN, Michaelis M, Cinatl J Jr.. Aprotinin Inhibits SARS-CoV-2 Replication. Cells. 2020A Oct 30;9(11):2377. doi: 10.3390/cells9112377.
    OpenUrlCrossRef
  11. ↵
    Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2021 Jan 21;10(2):206.
    OpenUrl
  12. ↵
    Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361, 2045–6.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Cinatl, J. Jr..; Michaelis, M.; Morgenstern, B.; Doerr, H.W. High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells. Int. J. Mol. Med. 2005, 15, 323–327.
    OpenUrlPubMed
  14. ↵
    Cooper DKC, Hara H, Iwase H, Yamamoto T, Li Q, Ezzelarab M, Federzoni E, Dandro A, Ayares D. Justification of specific genetic modifications in pigs for clinical organ xenotransplantation. Xenotransplantation. 2019 Jul;26(4):e12516. doi: 10.1111/xen.12516.
    OpenUrlCrossRef
  15. ↵
    Cruz Rodriguez JB, Lange RA, Mukherjee D. Gamut of cardiac manifestations and complications of COVID-19: a contemporary review. J Investig Med. 2020 Dec;68(8):1334–1340. doi: 10.1136/jim-2020-001592.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Devarasetti PK, Rajasekhar L, Baisya R, Sreejitha KS, Vardhan YK. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. Immunol Res. 2021 Jan 25:1–8. doi: 10.1007/s12026-020-09169-x.
    OpenUrlCrossRef
  17. ↵
    Dong, E.; Du, H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020, 20, 533–534.
    OpenUrlCrossRefPubMed
  18. ↵
    Fabrizi F, Alfieri CM, Cerutti R, Lunghi G, Messa P. COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Pathogens. 2020 Dec 15;9(12):1052. doi: 10.3390/pathogens9121052.
    OpenUrlCrossRef
  19. ↵
    Feng R, Zhao H, Xu J, Shen C. CD47: the next checkpoint target for cancer immunotherapy. Crit Rev Oncol Hematol. 2020 Aug;152:103014. doi: 10.1016/j.critrevonc.2020.103014.
    OpenUrlCrossRef
  20. ↵
    Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, Frazier WA. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol. 2011 Mar;30(2):154–61. doi: 10.1016/j.matbio.2010.12.004.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Gao Q, Chen K, Gao L, Zheng Y, Yang YG. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. Cell Death Dis. 2016 Sep 8;7(9):e2368. doi: 10.1038/cddis.2016.155.
    OpenUrlCrossRef
  22. ↵
    Ghimire K, Li Y, Chiba T, Julovi SM, Li J, Ross MA, Straub AC, O’Connell PJ, Rüegg C, Pagano PJ, Isenberg JS, Rogers NM. CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis. Cells. 2020 Jul 15;9(7):1695. doi: 10.3390/cells9071695.
    OpenUrlCrossRef
  23. ↵
    Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021 Jan;191(1):4–17. doi: 10.1016/j.ajpath.2020.08.009.
    OpenUrlCrossRef
  24. ↵
    Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2020 Oct 8:100761. doi: 10.1016/j.blre.2020.100761.
    OpenUrlCrossRef
  25. ↵
    Hoehl, S.; Berger, A.; Kortenbusch, M.; Cinatl, J.; Bojkova, D.; Rabenau, H.; Behrens, P.; Böddinghaus, B.; Götsch, U.; Naujoks, F.; Neumann, P.; Schork, J.; Tiarks-Jungk, P.; Walczok, A.; Eickmann, M.; Vehreschild, M.J.G.T.; Kann, G.; Wolf, T.; Gottschalk, R.; Ciesek, S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N. Engl. J. Med. 2020, 382, 1278–1280.
    OpenUrlCrossRefPubMed
  26. ↵
    Hokello J, Sharma AL, Shukla GC, Tyagi M. A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. Ann Transl Med. 2020 Dec;8(24):1686.
    OpenUrl
  27. ↵
    Hosny N, Matson AW, Kumbha R, Steinhoff M, Sushil Rao J, El-Abaseri TB, Sabek NA, Mahmoud MA, Hering BJ, Burlak C. 3’UTR enhances hCD47 cell surface expression, self-signal function, and reduces ER stress in porcine fibroblasts. Xenotransplantation. 2021 Jan;28(1):e12641.
    OpenUrl
  28. ↵
    Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2582–8. doi: 10.1161/ATVBAHA.107.155390.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci. 2008 Mar;65(5):728–42. doi: 10.1007/s00018-007-7488-x.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J, Frazier WA, Roberts DD. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol. 2009 Mar;28(2):110–9. doi: 10.1016/j.matbio.2009.01.002.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Jacques FH, Apedaile E. Immunopathogenesis of COVID-19: Summary and Possible Interventions. Front Immunol. 2020 Sep 17;11:564925. doi: 10.3389/fimmu.2020.564925.
    OpenUrlCrossRef
  32. ↵
    Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Goepfert P, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020 Dec 11:NEJMoa2031994. doi: 10.1056/NEJMoa2031994.
    OpenUrlCrossRef
  33. ↵
    Karmouty-Quintana H, Thandavarayan RA, Keller SP, Sahay S, Pandit LM, Akkanti B. Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. Int J Mol Sci. 2020 Oct 29;21(21):8081. doi: 10.3390/ijms21218081.
    OpenUrlCrossRef
  34. ↵
    Kaur S, Cicalese KV, Bannerjee R, Roberts DD. Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment. Antib Ther. 2020 Jul;3(3):179–192. doi: 10.1093/abt/tbaa017.
    OpenUrlCrossRef
  35. ↵
    Kemp SA, Collier DA, Datir R, Ferreira I, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N, Sharrocks K, Blane E, Briggs J, van Gils MJ, Smith K, Bradley JR, Smith C, Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth C, McCoy LE, Gupta RK. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv. 2020 Dec 29:2020.12.05.20241927. doi: 10.1101/2020.12.05.20241927.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Leeming DJ, Genovese F, Sand JMB, Rasmussen DGK, Christiansen C, Jenkins G, Maher TM, Vestbo J, Karsdal MA. Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis. Respir Res. 2021 Feb 5;22(1):38. doi: 10.1186/s12931-020-01590-y.
    OpenUrlCrossRef
  37. ↵
    Liu Z, VanBlargan LA, Rothlauf PW, Bloyet LM, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv. 2020 Nov 8:2020.11.06.372037. doi: 10.1101/2020.11.06.372037.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Maile LA, Capps BE, Miller EC, Aday AW, Clemmons DR. Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo. Diabetes. 2008 Oct;57(10):2637–43. doi: 10.2337/db08-0326.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Maile LA, Allen LB, Veluvolu U, Capps BE, Busby WH, Rowland M, Clemmons DR. Identification of compounds that inhibit IGF-I signaling in hyperglycemia. Exp Diabetes Res. 2009;2009:267107. doi: 10.1155/2009/267107.
    OpenUrlCrossRefPubMed
  40. ↵
    Maile LA, Allen LB, Hanzaker CF, Gollahon KA, Dunbar P, Clemmons DR. Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation. Exp Diabetes Res. 2010;2010:617052. doi: 10.1155/2010/617052.
    OpenUrlCrossRef
  41. ↵
    Maile LA, Gollahon K, Wai C, Byfield G, Hartnett ME, Clemmons D. Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. Diabetologia. 2012 Mar;55(3):835–44. doi: 10.1007/s00125-011-2416-x.
    OpenUrlCrossRefPubMed
  42. ↵
    Maimaitiyiming H, Norman H, Zhou Q, Wang S. CD47 deficiency protects mice from diet-induced obesity and improves whole body glucose tolerance and insulin sensitivity. Sci Rep. 2015 Mar 9;5:8846. doi: 10.1038/srep08846.
    OpenUrlCrossRef
  43. ↵
    Meijles DN, Sahoo S, Al Ghouleh I, Amaral JH, Bienes-Martinez R, Knupp HE, Attaran S, Sembrat JC, Nouraie SM, Rojas MM, Novelli EM, Gladwin MT, Isenberg JS, Cifuentes-Pagano E, Pagano PJ. The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal. 2017 Oct 17;10(501):eaaj1784. doi: 10.1126/scisignal.aaj1784.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol. 2010 Apr;159(7):1542–7. doi: 10.1111/j.1476-5381.2009.00631.x.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    Nevitt C, McKenzie G, Christian K, Austin J, Hencke S, Hoying J, LeBlanc A. Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats. Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1842–50. doi: 10.1152/ajpheart.00086.2016.
    OpenUrlCrossRefPubMed
  46. ↵
    Norman-Burgdolf H, Li D, Sullivan P, Wang S. CD47 differentially regulates white and brown fat function. Biol Open. 2020 Dec 16;9(12):bio056747. doi: 10.1242/bio.056747.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Novelli EM, Little-Ihrig L, Knupp HE, Rogers NM, Yao M, Baust JJ, Meijles D, St Croix CM, Ross MA, Pagano PJ, DeVallance ER, Miles G, Potoka KP, Isenberg JS, Gladwin MT. Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1150–L1164. doi: 10.1152/ajplung.00302.2018.
    OpenUrlCrossRef
  48. ↵
    Nowill AE, de Campos-Lima PO. Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. J Immunol. 2020 Nov 15;205(10):2566–2575. doi: 10.4049/jimmunol.2000892.
    OpenUrlAbstract/FREE Full Text
  49. Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ. Just eat it: A review of CD47 and SIRP-α antagonism. Semin Oncol. 2020 Apr-Jun;47(2-3):117–124. doi: 10.1053/j.seminoncol.2020.05.009.
    OpenUrlCrossRef
  50. ↵
    Oronsky B, Knox S, Cabrales P, Oronsky A, Reid TR. Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. Semin Oncol. 2020a Oct;47(5):305–308. doi: 10.1053/j.seminoncol.2020.07.002.
    OpenUrlCrossRef
  51. ↵
    Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. Biomolecules. 2021 Jan 12;11(1):91. doi: 10.3390/biom11010091.
    OpenUrlCrossRef
  52. ↵
    Rebold N, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. Infect Dis Ther. 2021 Jan 25. doi: 10.1007/s40121-021-00399-6.
    OpenUrlCrossRef
  53. ↵
    RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
    OpenUrlCrossRefPubMed
  54. ↵
    Rogers NM, Roberts DD, Isenberg JS. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg. 2013 Jul;258(1):184–91. doi: 10.1097/SLA.0b013e31827e52e1.
    OpenUrlCrossRefPubMed
  55. ↵
    Rogers NM, Yao M, Sembrat J, George MP, Knupp H, Ross M, Sharifi-Sanjani M, Milosevic J, St Croix C, Rajkumar R, Frid MG, Hunter KS, Mazzaro L, Novelli EM, Stenmark KR, Gladwin MT, Ahmad F, Champion HC, Isenberg JS. Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension. Pulm Circ. 2013a Dec;3(4):936–51. doi: 10.1086/674754.
    OpenUrlCrossRefPubMed
  56. ↵
    Rogers NM, Sharifi-Sanjani M, Yao M, Ghimire K, Bienes-Martinez R, Mutchler SM, Knupp HE, Baust J, Novelli EM, Ross M, St Croix C, Kutten JC, Czajka CA, Sembrat JC, Rojas M, Labrousse-Arias D, Bachman TN, Vanderpool RR, Zuckerbraun BS, Champion HC, Mora AL, Straub AC, Bilonick RA, Calzada MJ, Isenberg JS. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction. Cardiovasc Res. 2017 Jan;113(1):15–29. doi: 10.1093/cvr/cvw218.
    OpenUrlCrossRefPubMed
  57. ↵
    Rogers NM, Ghimire K, Calzada MJ, Isenberg JS. Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease. Cardiovasc Res. 2017a Jul 1;113(8):858–868. doi: 10.1093/cvr/cvx094.
    OpenUrlCrossRef
  58. ↵
    Sabino EC, Buss LF, Carvalho MPS, Prete CA Jr., Crispim MAE, Fraiji NA, Pereira RHM, Parag KV, da Silva Peixoto P, Kraemer MUG, Oikawa MK, Salomon T, Cucunuba ZM, Castro MC, de Souza Santos AA, Nascimento VH, Pereira HS, Ferguson NM, Pybus OG, Kucharski A, Busch MP, Dye C, Faria NR. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021 Feb 6;397(10273):452–455. doi: 10.1016/S0140-6736(21)00183-5.
    OpenUrlCrossRefPubMed
  59. ↵
    Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. Epidemiology of SARS-CoV-2. Infection. 2020 Oct 8:1–7. doi: 10.1007/s15010-020-01531-3.
    OpenUrlCrossRef
  60. ↵
    Sanghvi SK, Schwarzman LS, Nazir NT. Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis. Diagnostics (Basel). 2021 Jan 15;11(1):130. doi: 10.3390/diagnostics11010130.
    OpenUrlCrossRef
  61. ↵
    Scutelnic A, Heldner MR. Vascular Events, Vascular Disease and Vascular Risk Factors-Strongly Intertwined with COVID-19. Curr Treat Options Neurol. 2020;22(11):40. doi: 10.1007/s11940-020-00648-y.
    OpenUrlCrossRef
  62. ↵
    Shah H, Khan MSH, Dhurandhar NV, Hegde V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 2021 Feb 15:1–13. doi: 10.1007/s00592-020-01636-z.
    OpenUrlCrossRef
  63. ↵
    Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets. 2013 Jan;17(1):89–103. doi: 10.1517/14728222.2013.733699.
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    Tal MC, Torrez Dulgeroff LB, Myers L, Cham LB, Mayer-Barber KD, Bohrer AC, Castro E, Yiu YY, Lopez Angel C, Pham E, Carmody AB, Messer RJ, Gars E, Kortmann J, Markovic M, Hasenkrug M, Peterson KE, Winkler CW, Woods TA, Hansen P, Galloway S, Wagh D, Fram BJ, Nguyen T, Corey D, Kalluru RS, Banaei N, Rajadas J, Monack DM, Ahmed A, Sahoo D, Davis MM, Glenn JS, Adomati T, Lang KS, Weissman IL, Hasenkrug KJ. Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. mBio. 2020 Jun 23;11(3):e01293–20. doi: 10.1128/mBio.01293-20.
    OpenUrlCrossRef
  65. ↵
    Toptan, T;. Hoehl, S.; Westhaus, S.; Bojkova, D.; Berger, A.; Rotter, B.; Hoffmeier, K.; Cinatl, J. Jr..; Ciesek, S.; Widera, M. Optimized qRT-PCR Approach for the Detection of Intra-and Extra-Cellular SARS-CoV-2 RNAs. Int. J. Mol. Sci. 2020, 21, E4396.
    OpenUrl
  66. ↵
    Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec;12(1):1854149. doi: 10.1080/19420862.2020.1854149.
    OpenUrlCrossRefPubMed
  67. van Wetering, S.; van der Linden, A.C.; van Sterkenburg, M.A.; de Boer, W.I.; Kuijpers, A.L.; Schalkwijk, J.; Hiemstra, P.S. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278, L51–8.
    OpenUrlPubMedWeb of Science
  68. ↵
    Wang JM, Tao J, Chen DD, Cai JJ, Irani K, Wang Q, Yuan H, Chen AF. MicroRNA miR-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):99–109. doi: 10.1161/ATVBAHA.113.302104.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238–251. doi: 10.1056/NEJMoa2035002.
    OpenUrlCrossRefPubMed
  70. ↵
    Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
    OpenUrlCrossRefPubMed
  71. ↵
    Wernig G, Chen SY, Cui L, Van Neste C, Tsai JM, Kambham N, Vogel H, Natkunam Y, Gilliland DG, Nolan G, Weissman IL. Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci U S A. 2017 May 2;114(18):4757–4762. doi: 10.1073/pnas.1621375114.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Lambson BE, Vermeulen M, van den Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021 Jan 19:2021.01.18.427166. doi: 10.1101/2021.01.18.427166.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330–1341.
    OpenUrlCrossRefPubMed
Back to top
Posted March 01, 2021.
Download PDF

Supplementary Material

Email
CD47 as a potential biomarker for the early diagnosis of severe COVID-19
Katie-May McLaughlin, Denisa Bojkova, Marco Bechtel, Joshua D. Kandler, Philipp Reus, Trang Le, Julian U. G. Wagner, Sandra Ciesek, Mark N. Wass, Martin Michaelis, Jindrich Cinatl jr.
bioRxiv 2021.03.01.433404; doi: https://doi.org/10.1101/2021.03.01.433404
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area